Management of apixaban toxicity involves supportive care and, if necessary, the administration of specific reversal agents. The introduction of andexanet alfa, a recombinant modified human Factor Xa protein, serves as a reversal agent for apixaban in cases of life-threatening or uncontrolled bleeding. Additionally, activated charcoal may be used if the overdose is identified within a short timeframe, as it can help reduce absorption from the gastrointestinal tract.
